Has Aqeel Hashmi, MD received payments from drug or device companies?

Yes. Drug and device makers reported $5,814 in general payments to Aqeel Hashmi, MD across 184 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Aqeel Hashmi, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Aqeel Hashmi, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Aqeel Hashmi, MD

Psychiatry · Houston, TXNPI 1083900955

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $4,048 of the $5,814 with a category attached, or 69.6%. 14 manufacturers reported payments, led by Neurocrine Biosciences, Inc. at 39.1% of the total. 2025 is the largest year on record at $3,419, more than ten times the $308 reported in 2019.

$5,814in general payments, 2019–2025

Across 184 payments — averaging $31.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Neurocrine Biosciences, Inc.$2K
Johnson & Johnson$883
Alkermes, Inc.$534
Teva Pharmaceuticals USA, Inc.$519
Otsuka America Pharmaceutical, Inc.$445
AbbVie$423
plus $735 from 8 others

$1,310,674in research payments, 2019–2025

Across 265 payments — averaging $4945.94 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

E.r. Squibb & Sons, L.L.C.$592K
Boehringer Ingelheim$357K
Janssen Research & Development, LLC$102K
AbbVie$59K
Boehringer Ingelheim International GmbH$47K
Teva Pharmaceuticals USA, Inc.$37K
plus $116K from 7 others

What the payments were for

Travel & lodging$1,63228%
Food & beverage$4,04870%
Education$1352%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Neurocrine Biosciences, Inc.	20	$2,274
Johnson & Johnson	32	$883
Alkermes, Inc.	27	$534
Teva Pharmaceuticals USA, Inc.	23	$519
Otsuka America Pharmaceutical, Inc.	22	$445
AbbVie	23	$423
E.r. Squibb & Sons, L.L.C.	12	$259
Takeda Pharmaceuticals U.S.A., Inc.	7	$126
Indivior Inc.	6	$106
Axsome Therapeutics, Inc.	4	$77
Lundbeck LLC	2	$56
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	2	$49
Vanda Pharmaceuticals Inc.	3	$47
Luye Pharma (USA) Ltd.	1	$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,814 in reported general payments places this provider in the 85th percentile of 2,238 psychiatry providers in Texas.

See all psychiatry providers in Texas →

Medicare billing

Part B allowed, 2024

$45,353

Medicare patients

100

Services billed

490

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Aripiprazole	12	$858
Clonazepam	71	$708
Duloxetine Hcl	22	$655
Quetiapine Fumarate	42	$499
Mirtazapine	20	$472
Olanzapine	17	$456
Hydroxyzine Hcl	12	$371
Zolpidem Tartrate	35	$339
Venlafaxine Hcl ErVenlafaxine Hcl	20	$314
Escitalopram Oxalate	18	$218
Trazodone Hcl	21	$205
Buspirone Hcl	14	$197
Lorazepam	11	$135
Risperidone	11	$87

Paid to pharmacies, not to this prescriber.

Other psychiatry in Houston

Matthew BramsHouston$1.5M
Frank ChenHouston$941K
Alice MaoHouston$850K
Mazhar KhowajaHouston$843K
Barry GritzHouston$792K
Aaron PetersonHouston$700K
Ayesha RashidHouston$641K
Lawrence GinsbergHouston$502K
Kathy FlanaganHouston$443K
Rayan Al JurdiHouston$359K

See the full list for Texas →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →